Autologous stem cell therapy - Regeneration Biomedical
Alternative Names: Autologous adipose-derived stem cells - Regeneration Biomedical; RB-ADSCLatest Information Update: 13 May 2025
At a glance
- Originator Regeneration Biomedical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alzheimer's disease
- Research Amyotrophic lateral sclerosis; Multiple sclerosis; Stroke; Traumatic brain injuries
Most Recent Events
- 05 May 2025 Interim efficacy and adverse event data from a phase I trial in Alzheimer's disease released by Regeneration Biomedical
- 05 Apr 2025 Efficacy and adverse events data from a phase-I trial in Alzheimer's disease presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
- 29 Oct 2024 Efficacy data from a phase I trial in Alzheimer's disease were released by Regeneration Biomedical